GS-9911(GS-9911) - 药物靶点：DGKA_在研适应症：实体瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

GS 9911、GS9911

靶点

DGKA

作用机制

DGKA抑制剂(diacylglycerol kinase alpha inhibitors)

治疗领域

肿瘤

在研适应症

实体瘤

非在研适应症-

原研机构

Gilead Sciences, Inc.

Carna Biosciences, Inc.

在研机构

Gilead Sciences, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 GS-9911 相关的临床试验

NCT06082960 / Recruiting临床1期

A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors.
The primary objectives of this study are to:
* Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors
* Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors

开始日期2023-10-09

申办/合作机构

Gilead Sciences, Inc.

100 项与 GS-9911 相关的临床结果

登录后查看更多信息

100 项与 GS-9911 相关的转化医学

登录后查看更多信息

100 项与 GS-9911 相关的专利（医药）

登录后查看更多信息

100 项与 GS-9911 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	临床1期	美国	Gilead Sciences, Inc.	2023-10-09
实体瘤	临床1期	澳大利亚	Gilead Sciences, Inc.	2023-10-09
实体瘤	临床1期	加拿大	Gilead Sciences, Inc.	2023-10-09